Company intelligence / Profile preview

CoreMedic

Radolfzell am Bodensee, Baden-Württemberg, Germanycoremedic.de ↗

Ownership: Private
Development stage: Phase 1

Overview

CoreMedic has developed ChordArt, a transcatheter device designed to replace damaged or elongated mitral valve chords in patients with mitral regurgitation. The company launched its first-in-human study in 2018 and continues to advance clinical development with recent Series B funding. Initial results from the first patient treated showed successful implantation and recovery without complications at 30 days[3][4].

Therapeutic areas: Cardiovascular
Modalities: Device (Transcatheter mitral valve repair system)
Industry: Implantable Medical Devices

Drug pipeline

1 asset

ChordArt

Phase 1

Indications: Mitral valve regurgitation

Partnerships

MIG Capital AGSHS Gesellschaft für Beteiligungsmanagement mbH

Beyond the preview

Go deeper on CoreMedic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CoreMedic.

Explore the full profile